DSHEA vs. NPN: Where Raw Material Testing Requirements Diverge for Midwest Supplement Brands

A contract manufacturer in the Chicago suburb of Bolingbrook ran a spotless FDA inspection record for six consecutive years — no 483s, clean cGMP audits, documented raw material testing across every botanical ingredient they processed. Then they landed a Canadian brand owner as a new client. Within 90 days, they were rebuilding their documentation package from scratch after discovering that three of their standard raw material identity methods weren’t directly accepted in the Health Canada Compendium of Monographs — and that their ICP-MS reporting template wasn’t flagging against the right elemental limits for NHP compliance.

The experience isn’t unusual. Among Midwest supplement brands expanding into Canadian retail or Amazon.ca, the assumption that DSHEA compliance transfers cleanly across the border is persistent — and consistently expensive to unlearn. Both frameworks require raw material identity testing, both demand GMP manufacturing conditions, and both expect a documented chain of custody. But the technical specifications — acceptable methods, applicable limits, what documentation a regulator needs to see — diverge in ways that create real audit exposure.

Here’s where the gaps actually are.

The Two Regulatory Frameworks at a Glance

DSHEA (the Dietary Supplement Health and Education Act, enacted 1994) established the legal foundation for US dietary supplements, but the manufacturing requirements brands actually operate under come from 21 CFR Part 111 — the Current Good Manufacturing Practice regulations finalized by FDA in 2007. Under Part 111, manufacturers are responsible for verifying that every incoming component meets established specifications before use in production.

Health Canada’s Natural Health Products Regulations (SOR/2003-196), in force since 2004, govern natural health products (NHPs) — a category that roughly corresponds to US dietary supplements but is defined independently. NHPs include herbal remedies, vitamins and minerals, homeopathic preparations, traditional medicines, and probiotics. Both the manufacturer and the importer of an NHP require a site licence; every marketed product requires its own product licence, which carries the NPN (Natural Product Number) appearing on Canadian labels.

From a raw material testing standpoint, both regimes require incoming lot verification. Where they differ is in the details.

Where DSHEA and NHP Requirements Actually Diverge

Identity Testing: Method Flexibility vs. Compendium Alignment

21 CFR 111.75(a)(1)(i) is unambiguous: before using any component, a manufacturer must conduct at least one appropriate test to verify identity. FDA’s enforcement position — visible across warning letters going back to 2011 — is that a supplier’s CoA alone does not satisfy this requirement. You need independent testing data on every lot.

Health Canada’s NHP GMP requirements (Schedule 2 of SOR/2003-196) also mandate per-lot identity testing. But Health Canada publishes a Compendium of Monographs that specifies preferred analytical methods for listed botanical ingredients. If your formula uses an herb with a Compendium monograph, deviating from those reference methods requires explicit justification in your product licence application — justification that needs to be technically detailed, not simply asserted.

In practice, an HPTLC result that satisfies a US cGMP auditor may need supplementary method validation documentation if a Health Canada reviewer picks up the file. For multi-ingredient botanical formulas — a 6-herb adaptogen blend, for instance — this can mean 10–12 method justification records per lot, compared to the 3–5 records a US audit typically requires.

Elemental Impurities: USP PDEs vs. Compendium Concentration Limits

Under 21 CFR Part 111, FDA doesn’t set specific heavy metal limits in the regulation itself. Instead, manufacturers establish elemental specifications based on recognized scientific standards — in practice, that means USP <232> (Elemental Impurities — Limits) and USP <233> (Elemental Impurities — Procedures), with ICP-MS as the method of choice for multi-element screening.

USP <232> sets oral route permitted daily exposure (PDE) limits for Class 1 elements. For the three most scrutinized: lead at 5 μg/day, inorganic arsenic at 15 μg/day, and cadmium at 2 μg/day. Those PDEs translate into raw material concentration limits based on daily dose and formula loading — a calculation each manufacturer must perform and document for each ingredient.

Health Canada takes a more prescriptive approach. The Compendium of Monographs publishes element-specific limits directly in ppm (mg/kg) for individual botanicals, and for certain ingredient categories — particularly seaweed-derived ingredients and Ayurvedic herbs with known elemental accumulation patterns — those limits are more conservative than what a USP <232> PDE-based calculation yields at typical use levels.

The practical implication: if you’re using one analytical testing lab and one ICP-MS panel for raw material release, your reporting template needs to check compliance against both limit sets simultaneously. A lot that passes your USP <232>-based US specification might still fail the Health Canada Compendium limit for that specific botanical. You can’t catch this during an audit. It needs to be flagged at incoming inspection, which means the dual-specification comparison has to be baked into your CoA template before any lot ships north.

Microbial Limits: Broadly Aligned, but With Edge Cases That Matter

Both regimes require microbial limits testing on incoming botanical raw materials, and both follow broadly similar methodology: total aerobic microbial count (TAMC), total combined yeast and mold count (TYMC), and specified organism testing for Salmonella, E. coli, and others. Under 21 CFR Part 111, manufacturers follow USP <61>, <62>, and <2021> for both method and acceptance criteria.

For most botanical raw materials, Health Canada’s microbial limits align closely with USP <2021> category guidelines. The edge cases emerge with traditional herbal ingredient categories — certain Ayurvedic and traditional Chinese medicine ingredient classes — where Health Canada has published specific organism requirements that don’t map directly to any USP chapter. A USP-complete microbial test package may need additional tests appended before the same lot satisfies NHP compliance.

High-bioburden botanicals deserve particular attention here. Valerian root, slippery elm bark, and unprocessed seeds naturally carry elevated ambient microbial loads. A lot that barely passes under one framework’s limits may not clear both without a bioburden reduction step — and discovering that during product licence review rather than at incoming inspection creates serious schedule pressure.

Documentation: The Designated QA Person Gap

21 CFR Part 111 requires that raw material records document: component identity, lot number, supplier information, supplier CoA, your own testing results, and the disposition decision. Most supplement manufacturers running solid US cGMP programs have all of this.

Health Canada’s NHP GMP requirements add an element with no clean equivalent in US cGMP: the designation of a specific, named individual with documented authority over quality assurance and product release decisions. Under FDA’s framework, a QC Director or Laboratory Director signing batch records satisfies the agency as long as the role is defined in the quality system. Health Canada expects the individual’s name, qualifications, and specific authority to appear in both the site licence application and the batch records themselves.

For companies relying on a contract analytical testing laboratory for raw material release decisions, this means the sign-off chain needs to be explicitly mapped in your SOPs — not inferred from an org chart. If the person signing your incoming lot disposition records changes roles, Health Canada wants that reflected in your site licence, not just your internal HR files.

Building One Analytical Testing Program That Satisfies Both Markets

The good news is that a well-designed raw material testing program can cover both frameworks without doubling your analytical spend. The key is building your specifications table to include both limit sets from the start — USP <232> PDEs and the relevant Health Canada Compendium limits for each botanical you source — with dual-compliance flagging built into your CoA template.

For botanical identity, HPTLC with documented reference standard comparisons — following AHPA and USP botanical identity monographs where available — satisfies both FDA and Health Canada when method validation data is on file. DNA barcoding is increasingly used as supplementary evidence under both regimes, though neither has fully standardized it as a standalone identity method. Running both adds depth to your identity file and signals seriousness to reviewers on either side of the border.

For elemental impurities, a 24-element ICP-MS screen reported against both limit sets adds no analytical cost — it’s a report template design decision, not a second assay. The time to build that into your template is before your first NPN product licence submission, not during the back-and-forth of an incomplete application.

For microbiology, a USP <61>/<62>/<2021>-compliant panel covers the majority of botanical raw materials under both frameworks. The edge cases — traditional ingredient categories with Health Canada-specific organism requirements — are identifiable in advance by reviewing the relevant Compendium monographs before you finalize your ingredient list.

The documentation gap — named QA designee, method justification for non-Compendium approaches — is best addressed before you file for NPN licensing, not after your first deficiency notice. Retroactively building dual-compliant records for historical lots is significantly more expensive than designing the program correctly upfront.

If you’re a Midwest brand currently selling exclusively in the US but treating Canada as a growth market, auditing your raw material testing program against both frameworks now is worth the afternoon it takes. The gaps are usually narrower than they appear on paper — but they’re real, and regulators on both sides of the border have seen enough cross-border non-compliance to know exactly where to look.

---

Written by Nour Abochama, VP Operations, Qalitex | Quality Consultant, Ayah Labs. Learn more about our team

Ship your sample to our Chicago facility — get a Qalitex CoA in 5–7 days Contact us

Related from our network

• ISO 17025-accredited raw material testing and supplement CoAs — Qalitex Laboratories performs the full analytical program behind Ayah Labs’ Chicago receiving hub, including ICP-MS, HPTLC botanical identity, and USP microbiology panels for both US and Canadian compliance.